What is ClearPoint Neuro's gross profit margin?

What is ClearPoint Neuro's latest dividend and current dividend yield?

What factors drove the changes in ClearPoint Neuro's revenue and profit?

What is the revenue and EPS growth rate for ClearPoint Neuro year over year?

What is the market's earnings forecast for ClearPoint Neuro next quarter?

Did ClearPoint Neuro beat or miss consensus estimates last quarter?

What were the key takeaways from ClearPoint Neuro's earnings call?

What were the key takeaways from ClearPoint Neuro’s earnings call?

- **$500M Neurocritical Care Expansion**: Acquired IRRAS to enter $500M+ intracranial fluid management market with 83% YoY growth and <5% share.
- **$8.9M Q3 Revenue**: 9% YoY growth driven by 20% neurosurgery navigation and 25% capital equipment sales.
- **2026 Guidance**: $54-60M revenue (post-merger), targeting 70%+ gross margin through scale.
- **CRO Facility Potential**: New facility enables $5-10M+ studies, with GLP services adding $10M+ annual revenue.
- **Cell/Gene Therapy Pipeline**: Supporting 20+ indications, including 7 under FDA expedited review, with 2.1M U.S. patients eligible.

**【CEO Opening Remarks】**
- Announced merger with IRRAS, a leader in neurocritical care, to expand into a $500M+ market for intracranial fluid management. The deal includes $5M cash and 1.325M shares, with closing expected in Q4 2025.
- Introduced 2 strategic phases: 
  1. **Fast Forward**: Penetrate existing $1B+ market across 4 pillars (biologics/drug delivery, neurosurgery navigation, laser therapy, irrigation/aspiration) with <5% share.
  2. **Essential Everywhere**: Build a new $10B+ market for neuro drug delivery with biopharma partners.
- Highlighted IRRAS' 83% YoY growth and $9M run rate, with 40+ new commercial team members to be integrated.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $8.9M (+9% YoY), driven by 20% growth in neurosurgery navigation and 25% in capital equipment.
- Gross margin: 63% (vs. 60% YoY), up due to higher service revenue mix.
- R&D/S&M/G&A expenses increased 4%/8%/14% YoY, reflecting headcount expansion.
- Cash: $38.2M (vs. $20.1M at year-end 2024), supported by $32M in financing.
- 2025 full-year revenue guidance: $36-38M; 2026 pro forma revenue: $54-60M post-merger.

**【CEO Strategic Update】**
- **4 Pillar Growth Strategy**:
  1. **Pre-Commercial Biologics**: $300M market with <10% share; new CRO facility in Torrey Pines to support larger studies.
  2. **Neurosurgery Navigation & Robotics**: $125M market; launching 3.0 software, DUET Frame, and robotic platform.
  3. **Laser Therapy & Access**: $75M market; full release of PRISM system with 1.5T MRI compatibility.
  4. **Cranial Irrigation & Aspiration**: $500M market; IRRAS' IRRAflow system has <5% share but 83% YoY growth.
- **Cell/Gene Therapy Pipeline**: Supporting 20+ indications across 60+ biopharma partners, including 7 under FDA expedited review (e.g., AADC deficiency, Huntington's disease).
- 2026 revenue guidance: $54-60M (includes IRRAS), with >20% CAGR potential through market share gains.

**【Q&A Highlights】**
- **Neurocritical Care Market**: 400K+ annual procedures in the U.S., with IRRAS' IRRAflow system offering active irrigation/aspiration to reduce clogs and hospital costs. Competes with legacy EVD systems lacking innovation.
- **2026 Revenue Breakdown**: ~$36M from ClearPoint, $18M from IRRAS (post-merger). Gross margin target: 70%+ as scale is achieved.
- **CRO Facility Impact**: New facility enables $5-10M+ studies vs. prior max of $2M. GLP studies and expanded services (e.g., histology) could add $10M+ annual revenue.
- **Burn Rate**: Mid-single-digit millions in 2026, declining as revenue grows. Integration costs limited to Q4 2025-Q1 2026.

ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CLPT

CLPT fundamentals

You can ask Aime